Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of VRd-Lite vs DRd in Frail/Intermediate Fit Newly Diagnosed Multiple Myeloma
NCT05561387Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Oct 2023
- Primary completion
- May 2031
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Darzalex Faspro in multiple myeloma (MM), sponsored by SWOG Cancer Research Network. Started Oct 2023; status: recruiting.
02
Drugs
Darzalex Faspro
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05561387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561387.